Commodore Capital LP — 13F Holdings & Portfolio
CIK 1831942 · latest 13F-HR filed 2026-08-14
Commodore Capital LP manages $1.68B in 13F-reported U.S. long-equity assets across 33 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are RLAY (13.37%), ELVN (9.90%), ALKS (9.36%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 5 new positions and exited 8; 15 existing positions rose in reported value and 9 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 68.2%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 31, 2026.
35TH FLOOR
NEW YORK, NY 10022
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| Atkinson, Robert Egen, Turrell Control | MANAGING PARTNER since Jun 2019 | Less than 5% | Individual |
| COMMODORE CAPITAL GP LLC Control | GENERAL PARTNER since Jun 2019 | Less than 5% | Domestic Entity |
| Kramarz, Michael, Jonathan Control | MANAGING PARTNER since Jun 2019 | Less than 5% | Individual |
| Bapat, Ameya, Vikas | CHIEF COMPLIANCE OFFICER, CHIEF OPERATING OFFICER, GENERAL COUNSEL since Mar 2022 | Less than 5% | Individual |
| COMMODORE CAPITAL HOLDINGS LP | LIMITED PARTNER since Jun 2019 | 75% or more | Domestic Entity |
| Pandya, Anand, Bharat | CHIEF FINANCIAL OFFICER since Feb 2023 | Less than 5% | Individual |
| Atkinson, Robert Egen, Turrell Control Indirect owner via COMMODORE CAPITAL HOLDINGS LP | LIMITED PARTNER since Jun 2019 | 25–50% | Individual |
| Atkinson, Robert Egen, Turrell Control Indirect owner via COMMODORE CAPITAL GP LLC | MEMBER since Jun 2019 | 25–50% | Individual |
| Kramarz, Michael, Jonathan Control Indirect owner via COMMODORE CAPITAL HOLDINGS LP | LIMITED PARTNER since Jun 2019 | 25–50% | Individual |
Ownership & leadership changes · 5 filings with changes since Jul 15, 2019
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- No longer listedKramarz, Michael, Jonathan · MEMBER · 25–50% · indirect via COMMODORE CAPITAL GP LLC · control person · listed since Jun 2019
- ChangedBapat, Ameya, Vikas · title CHIEF COMPLIANCE OFFICER → CHIEF COMPLIANCE OFFICER, CHIEF OPERATING OFFICER, GENERAL COUNSEL
- No longer listedBARAKETT, TIMOTHY, ROBERT · DIRECTOR · General partner, trustee or manager · indirect via COMMODORE CAPITAL GP LLC · listed since Jun 2019
- No longer listedGLASS, ROBERT, A · CHIEF FINANCIAL OFFICER · Less than 5% · listed since Jun 2019
- AddedPandya, Anand, Bharat · CHIEF FINANCIAL OFFICER · Less than 5%
- ChangedAtkinson, Robert Egen, Turrell · indirect via COMMODORE CAPITAL GP LLC: title MEMBER AND DIRECTOR → MEMBER
- ChangedKramarz, Michael, Jonathan · indirect via COMMODORE CAPITAL GP LLC: title MEMBER AND DIRECTOR → MEMBER
- No longer listedHENDERSON, CHRISTINA, MARIE · CHIEF COMPLIANCE OFFICER · Less than 5% · listed since Jun 2019
- AddedBapat, Ameya, Vikas · CHIEF COMPLIANCE OFFICER · Less than 5%
- No longer listedDUBIN, GLENN, RUSSELL · DIRECTOR · General partner, trustee or manager · indirect via COMMODORE CAPITAL GP LLC · listed since Jun 2019
- ListedAtkinson, Robert Egen, Turrell · MANAGING PARTNER · Less than 5% · control person
- ListedAtkinson, Robert Egen, Turrell · LIMITED PARTNER · 25–50% · indirect via COMMODORE CAPITAL HOLDINGS LP · control person
- ListedAtkinson, Robert Egen, Turrell · MEMBER AND DIRECTOR · 25–50% · indirect via COMMODORE CAPITAL GP LLC · control person
- ListedBARAKETT, TIMOTHY, ROBERT · DIRECTOR · General partner, trustee or manager · indirect via COMMODORE CAPITAL GP LLC
- ListedCOMMODORE CAPITAL GP LLC · GENERAL PARTNER · Less than 5% · control person
- ListedCOMMODORE CAPITAL HOLDINGS LP · LIMITED PARTNER · 75% or more
- ListedDUBIN, GLENN, RUSSELL · DIRECTOR · General partner, trustee or manager · indirect via COMMODORE CAPITAL GP LLC
- ListedGLASS, ROBERT, A · CHIEF FINANCIAL OFFICER · Less than 5%
- ListedHENDERSON, CHRISTINA, MARIE · CHIEF COMPLIANCE OFFICER · Less than 5%
- ListedKramarz, Michael, Jonathan · MANAGING PARTNER · Less than 5% · control person
- ListedKramarz, Michael, Jonathan · LIMITED PARTNER · 25–50% · indirect via COMMODORE CAPITAL HOLDINGS LP · control person
- ListedKramarz, Michael, Jonathan · MEMBER AND DIRECTOR · 25–50% · indirect via COMMODORE CAPITAL GP LLC · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- DEFINIUM THERAPEUTICS INC$56.3M +148.9%
- RELAY THERAPEUTICS INC$55.4M +32.7%
- ENLIVEN THERAPEUTICS INC$37.8M +29.5%
- EYEPOINT INC$29.4M +80.6%
- AMYLYX PHARMACEUTICALS INC$22.9M +29.2%
Top Trims
- NUVALENT INC-$73.1M -85.5%
- CELLDEX THERAPEUTICS INC NEW-$35.3M -41.3%
- TYRA BIOSCIENCES INC-$34.9M -36.8%
- KYMERA THERAPEUTICS INC-$33.8M -54.1%
- SPYRE THERAPEUTICS INC-$21.3M -22.1%
New Positions
- TANGO THERAPEUTICS INC$70.3M
- EDITAS MEDICINE INC$28.8M
- INFLARX NV$16.4M
- RESEARCH ALLIANCE CORP III$5.3M
- VISTAGEN THERAPEUTICS INC$630.2K
Exited Positions
- ERASCA INC$51.4M
- XENON PHARMACEUTICALS INC$48.0M
- NURIX THERAPEUTICS INC$35.3M
- CORVUS PHARMACEUTICALS INC$33.0M
- SOLENO THERAPEUTICS INC$21.8M
Commodore Capital LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $224.5M | 13.37% | 12,000,000 | SH |
| 2 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $166.2M | 9.90% | 3,275,000 | SH |
| 3 | ALKERMES PLC | ALKS | G01767105 | $157.2M | 9.36% | 3,000,000 | SH |
| 4 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $118.0M | 7.03% | 3,050,000 | SH |
| 5 | AMYLYX PHARMACEUTICALS INC | AMLX | 03237H101 | $101.5M | 6.04% | 5,650,000 | SH |
| 6 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $94.1M | 5.60% | 2,000,000 | SH |
| 7 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $75.2M | 4.48% | 846,786 | SH |
| 8 | ALTO NEUROSCIENCE INC | ANRO | 02157Q109 | $71.9M | 4.28% | 2,723,196 | SH |
| 9 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $70.3M | 4.19% | 2,250,000 | SH |
| 10 | EYEPOINT INC | EYPT | 30233G209 | $65.8M | 3.92% | 4,600,000 | SH |
| 11 | TYRA BIOSCIENCES INC | TYRA | 90240B106 | $59.9M | 3.57% | 1,875,000 | SH |
| 12 | DAMORA THERAPEUTICS INC | DMRA | 36322Q206 | $50.4M | 3.00% | 1,939,000 | SH |
| 13 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $50.2M | 2.99% | 1,350,000 | SH |
| 14 | PHARVARIS N V | PHVS | N69605108 | $49.3M | 2.93% | 1,425,000 | SH |
| 15 | LB PHARMACEUTICALS INC | LBRX | 50180M108 | $48.7M | 2.90% | 1,500,000 | SH |
| 16 | ASSEMBLY BIOSCIENCES INC | ASMB | 045396207 | $38.9M | 2.32% | 1,415,000 | SH |
| 17 | EDITAS MEDICINE INC | EDIT | 28106W103 | $28.8M | 1.72% | 8,889,000 | SH |
| 18 | KYMERA THERAPEUTICS INC | KYMR | 501575104 | $28.7M | 1.71% | 250,000 | SH |
| 19 | PERSPECTIVE THERAPEUTICS INC | CATX | 46489V302 | $21.6M | 1.29% | 6,336,782 | SH |
| 20 | CENTURY THERAPEUTICS INC | IPSC | 15673T100 | $21.3M | 1.27% | 8,695,652 | SH |
| 21 | ZURA BIO LTD | ZURA | G9TY5A101 | $19.2M | 1.14% | 3,250,000 | SH |
| 22 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $18.8M | 1.12% | 1,018,319 | SH |
| 23 | INFLARX NV | IFRX | N44821101 | $16.4M | 0.97% | 7,300,000 | SH |
| 24 | AN2 THERAPEUTICS INC | ANTX | 037326105 | $14.2M | 0.85% | 2,933,680 | SH |
| 25 | NUVALENT INC | NUVL | 670703107 | $12.3M | 0.74% | 100,000 | SH |
| 26 | SAB BIOTHERAPEUTICS INC | SABS | 78397T202 | $11.2M | 0.67% | 2,870,000 | SH |
| 27 | INHIBIKASE THERAPEUTICS INC | IKT | 45719W205 | $11.0M | 0.65% | 5,397,488 | SH |
| 28 | RELMADA THERAPEUTICS INC | RLMD | 75955J402 | $9.9M | 0.59% | 1,425,000 | SH |
| 29 | PEPGEN INC | PEPG | 713317105 | $8.1M | 0.48% | 4,475,000 | SH |
| 30 | RESEARCH ALLIANCE CORP III | RACC | G75226103 | $5.3M | 0.32% | 500,000 | SH |
| 31 | HELIX ACQUISITION CORP III | HLXC | G4444S107 | $5.3M | 0.32% | 500,000 | SH |
| 32 | LEONABIO INC | LONA | 04746L203 | $4.3M | 0.25% | 464,398 | SH |
| 33 | VISTAGEN THERAPEUTICS INC | VTGN | 92840H400 | $630.2K | 0.04% | 2,788,620 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $1.68B | 33 | 0001831942-26-000033 |
| 2026-03-31 | 2026-05-15 | $1.73B | 36 | 0001831942-26-000025 |
| 2025-12-31 | 2026-02-17 | $1.50B | 33 | 0001831942-26-000004 |
| 2025-09-30 | 2025-11-14 | $2.05B | 37 | 0001831942-25-000023 |
35TH FLOOR
NEW YORK, NY 10022